Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

COVID-19 Vaccines Clinical Trial

Official title:

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults - Phase I Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05226390
• Other study ID #: MVA-S2-S-R01
• Status: Terminated
• Phase: Phase 1
• Start date: February 24, 2022
• Est. completion date: November 21, 2023

Study information

• Verified date: January 2024
• Source: Hannover Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a phase I, single-center trial, including a total of 30 participants in two cohorts. Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen. Cohort 2 (n=24): Healthy male or female adults aged 18 - ≤ 60 primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen and subsequently booster immunized with any EU marketed mRNA vaccine Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 23
• Est. completion date: November 21, 2023
• Est. primary completion date: November 21, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

The subject must not be enrolled before all inclusion criteria (including test results) are confirmed. Subjects meeting all of the criteria listed below will be included in the study.

1. Signed written informed consent from subject prior to any study-related procedure and willingness to comply with treatment and follow-up procedures

2. Healthy men or women, aged = 18 = 60 at day of inclusion having received either

1. primary immunization (cohort 1) with any regimen using any EU marketed SARS- CoV-2 vaccine or

2. subsequently booster immunization (cohort 2) with any EU marketed mRNA vaccine at least 3 months prior to enrollment

3. Adults with SARS-CoV-2 specific IgG concentration between 10 RU/ml and 1200 RU/ml determined by Anti-SARS-CoV-2-QuantiVac-ELISA (IgG)

4. Males or non-pregnant, non-lactating females of child-bearing potential with negative pregnancy test at screening who agree to comply with the applicable contraceptive requirements of the protocol (Section 3.4) from at least 14 days prior to vaccination and during the entire duration of the study. or

Females without child-bearing potential defined as follows:

• at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
• hysterectomy or uterine agenesis or
• = 50 years and in postmenopausal state > 1 year or
• < 50 years and in postmenopausal state > 1 year with serum FSH > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening

5. Normal pulmonary function: FEV1 predicted = 80% and FEV1/FVC > 70%

6. Body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening

7. Subject is capable of understanding the investigational nature, potential risks and benefits of the clinical trial Exclusion Criteria: Subjects are excluded from the study if any of the following criteria are met at screening or on dosing day.

1. Previous MVA or rMVA vaccination

2. Known allergy to the components of the SARS-CoV-2 vaccine product as chicken proteins or history of life-threatening reactions to vaccine containing the same substances

3. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine

4. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance; safety laboratory screening evaluation can be repeated a maximum of two times

5. Any finding in the medical history and physical examination deviating from normal and assessed as clinically relevant by the investigator

6. Evidence in the subject's medical history or in the medical examination that might influence the absorption, distribution, metabolism or excretion of the investigational medicinal product

7. Current smoking/ vaping or smoking /vaping in the previous year.

8. Clinically relevant findings in ECG

9. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes

10. Asthma, chronic obstructive pulmonary disease or other lung disease

11. Respiratory tract infection in the 4 weeks prior to study treatment

12. Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child

13. Known intolerance to medication used during bronchoscopy, i.e. midazolam and lidocaine.

14. Treatment with ß-adrenoceptor antagonists

15. Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)

16. Drug abuse or positive drug screening

17. Any positive result for HIV1/2, HCV antibody or HBs antigen testing

18. Moderate or severe illness and/or fever >38 °C within 1 week prior to vaccination

19. History of blood donation within 60 days of enrollment or plans to donate within the treatment phase

20. Participation in a clinical trial or use of an investigational product within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study

21. Investigator or employee of the study site or Sponsor with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study

Related Conditions & MeSH terms

• COVID-19 Vaccines

Intervention

Biological:
• MVA-SARS-2-ST
In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.

Locations

Country	Name	City	State
Germany	Hannover Medical School ZKS - Early Clinical Trial Unit at CRC Hannover	Hannover

Sponsors (4)

Lead Sponsor	Collaborator
Hannover Medical School	German Center for Infection Research, IDT Biologika, Universitätsklinikum Hamburg-Eppendorf

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 0
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 1
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 2
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 3
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 4
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 5
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 6
Primary	The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST	Occurrence of solicited local reactogenicity signs and symptoms	day 7
Primary	Change from baseline of pulmonary function associated with MVA-SARS-2-ST	Change from baseline of pulmonary function measured by spirometry as forced vital capacity (FVC) (%)	day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
Primary	Change from baseline of pulmonary function associated with MVA-SARS-2-ST	Change from baseline of pulmonary function measured by spirometry as forced expiratory volume in 1 second (FEV1) (%)	day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
Primary	Change from baseline of pulmonary function associated with MVA-SARS-2-ST	Change from baseline of pulmonary function measured by spirometry as FEV1/FVC (%)	day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
Primary	Change from baseline of pulmonary function associated with MVA-SARS-2-ST	Change from baseline of pulmonary function measured by peak flow as peak expiratory flow (PEF) frequently	day 0 and twice daily on days 1, 2, 3, 4, 5, 6, 7
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 0
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 1
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 2
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 3
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 4
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 5
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 6
Primary	Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST	Occurrence of solicited systemic reactogenicity signs and symptoms vaccination	day 7
Primary	Occurrence of unsolicited adverse events (AE) associated with MVA-SARS-2-ST	Occurrence of unsolicited adverse events (AE)	from day 0 to day 28 after vaccination
Primary	Change of safety laboratory measures associated with MVA-SARS-2-S	Change from baseline of safety laboratory measures	day 1, 3, 7, 14, 28, 56, 140
Primary	Occurrence of serious adverse events (SAE) associated with MVA-SARS-2-ST	Occurrence of serious adverse events (SAE)	through study completion, an average of 5 month
Secondary	To evaluate immunogenicity of the candidate MVA-SARS-2-ST	Change from baseline of levels of binding antibodies against SARS-CoV-2 spike S1 protein measured by ELISA in blood	day 7, 14, 28, 56 and 140
Secondary	To evaluate immunogenicity of the candidate MVA-SARS-2-ST	Change from baseline of levels of binding antibodies against SARS-CoV-2 spike S1 protein measured by ELISA in (bronchial alveolar lavage) BAL on day 14	day 14